Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises M42 on its acquisition of Diaverum from Bridgepoint
Mandate

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

May 22, 2023 M&A

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.

M42 is a global tech-enabled healthcare leader operating at the forefront of medical development. Diaverum is currently the world’s third-largest provider of dialysis services, operating across 23 countries, with 440 clinics and over 13,000 employees. The acquisition of Diaverum significantly expands M42’s global geographic footprint, enabling it to introduce relevant healthcare services and healthtech solutions in new markets while further enhancing its renal care offering in the GCC. The transaction, which is subject to customary regulatory approvals, is expected to close later in 2023.

Vinges team consisted of Matthias Pannier, Stina Bengtsson, Christoffer Nordin, Josefin Lanker och Josef Groow.

 

Related

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026

Vinge advises on the sale of Compab to Tången

 Vinge has advised the owners of Compab Energiteknik in connection with the sale of 80 per cent of the shares to Tången Industrikapital. Compab, which has a turnover of approximately SEK 100 million, sells, installs and services, amongst other things, steam and hot-water boilers as well as burners for the industrial sector.
October 26, 2026